Principal Financial Group Inc. Purchases 53,995 Shares of TransMedics Group, Inc. $TMDX

Principal Financial Group Inc. boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 28.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 242,039 shares of the company’s stock after buying an additional 53,995 shares during the period. Principal Financial Group Inc. owned 0.71% of TransMedics Group worth $27,157,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Marshall Wace LLP lifted its holdings in TransMedics Group by 258.7% in the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares in the last quarter. Zevenbergen Capital Investments LLC lifted its stake in TransMedics Group by 112.7% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after purchasing an additional 136,995 shares in the last quarter. Next Century Growth Investors LLC bought a new position in shares of TransMedics Group during the 2nd quarter valued at about $16,049,000. Goldman Sachs Group Inc. grew its position in shares of TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares in the last quarter. Finally, First Trust Advisors LP bought a new stake in shares of TransMedics Group in the second quarter worth about $5,815,000. Institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 8,920 shares of company stock worth $1,257,310. Company insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TMDX. Morgan Stanley increased their target price on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Jefferies Financial Group started coverage on TransMedics Group in a research report on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Needham & Company LLC lifted their target price on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Stock Performance

TMDX stock opened at $135.06 on Friday. TransMedics Group, Inc. has a twelve month low of $62.07 and a twelve month high of $156.00. The firm has a market cap of $4.62 billion, a price-to-earnings ratio of 54.68 and a beta of 2.06. The business’s fifty day simple moving average is $133.12 and its two-hundred day simple moving average is $124.36. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.